Allergic Rhinitis Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the allergic rhinitis drugs market size was valued at USD 12.72 billion in 2025 and is estimated to grow from USD 13.23 billion in 2026 to reach USD 16.47 billion by 2031, at a CAGR of 4.48% during the forecast period (2026-2031).

This report is Segmented by Drug Class (Antihistamines, Immunotherapy, Corticosteroids, and More), Dosage Form (Tablets & Capsules, Liquids & Syrups, Nasal Sprays, Nasal Drops, and More), Prescription Status (OTC, Rx), Distribution Channel (Drugstores & Retail Pharmacies, Hospital Pharmacies, and More), and Geography (North America, and More). Market Forecasts are Provided in Terms of Value (USD).

Global Allergic Rhinitis Drugs Market Trends and Insights

Longer Pollen Seasons Intensify Symptom Burden

Since 1990, the U.S. pollen season has lengthened by roughly three weeks, with spring arriving earlier and the first fall frost coming later. Europe shows a similar trend, with pollen counts now starting one to two weeks sooner than they did twenty years ago. A longer exposure window pushes many seasonal sufferers to take medicine for a larger part of the year. Work-safety rules also nudge employers to recommend non-sedating antihistamines and fast-acting nasal sprays instead of older, drowsiness-inducing drugs. Together, these forces steer patients toward once-daily leukotriene tablets or even multi-year sublingual immunotherapy, which lifts annual spending per patient.

Air Pollution Exacerbates Symptom Severity and Duration

Fine particles and nitrogen dioxide make pollen grains stickier and more irritating, which worsens allergic rhinitis symptoms. In Singapore, house-dust-mite sensitization touches 85% to 90% of residents, and more than half of people in humid Chinese coastal cities test positive as well. Weed pollen, particularly mugwort and ragweed, reaches up to 50% positivity in northern China skin tests. India shows a 20% to 30% allergic-rhinitis rate, with Parthenium pollen affecting up to one-third of patients in some regions. Elevated air pollution primes the nasal lining for quicker flare-ups and longer recovery, helping to explain why Asia-Pacific is projected to grow faster than any other region.

FDA Move Against Oral Phenylephrine Undercuts Decongestants

In late 2024, the FDA proposed pulling oral phenylephrine from the OTC monograph after advisors ruled the standard 10 mg dose ineffective. This ruling threatens hundreds of multi-symptom cold-and-allergy tablets and forces drugmakers to reformulate or exit the aisle. Pseudoephedrine still works but stays behind the counter because of methamphetamine controls, limiting spontaneous buys. Some companies are eyeing topical sprays such as oxymetazoline, yet the risk of rebound congestion after just a few days of use tempers long-term demand. Diversified firms like Haleon can pivot to antihistamine-steroid blends, while smaller brands that leaned on phenylephrine face shelf cuts and tighter margins.

Other drivers and restraints analyzed in the detailed report include:

1. E-commerce and Online Pharmacies Expand OTC Access
2. Rx-to-OTC Switches and Dual-Action Combination Sprays
3. Montelukast Boxed Warning Cools Prescriber Enthusiasm

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Antihistamines generated the largest allergic rhinitis drugs market size with 39.52% contribution in 2025, yet leukotriene receptor antagonists and biologics are escalating faster with 5.87% CAGR through 2031. Second-generation oral agents remain everyday staples, but boxed warnings and emerging IL-4/IL-13 inhibitors reshape clinician algorithms. Dupilumab's new rhinosinusitis label shows biologics can carve specialized niches with high reimbursement acceptance. Competitive pressure pushes innovators toward dual-action sprays and novel pathways, while generics sustain affordability for volume-driven antihistamines, keeping the allergic rhinitis drugs market balanced between accessibility and innovation.

Legacy decongestants face uncertainty, accelerating the pivot to combination nasal sprays that merge rapid relief with anti-inflammatory efficacy. Sublingual immunotherapy gains credibility through pediatric data and streamlined EU trial guidance, positioning the class to lift the allergic rhinitis drugs market share of disease-modifying treatments albeit from a low base.

Oral dosage forms such as tablets & capsules commanded nearly 46.87% share of 2025 revenue, reflecting the convenience premium consumers place on once-daily tablets. Yet nasal sprays and sublingual tablets headline innovation, posting the highest CAGRs as they align with patient desires for rapid onset or needle-free disease modification. The allergic rhinitis drugs market share for sprays is fortified by OTC switches, while SLIT tablets benefit from new pediatric indications.

Injectable SCIT retains a procedural niche but carries time burdens that hinder uptake; conversely, Health Canada's approval of a nasal epinephrine spray highlights patient enthusiasm for on-demand, device-free delivery modalities. These dynamics signal continued diversification of formats inside the allergic rhinitis drugs market.

Geography Analysis

North America remains the largest regional node, responsible for 38.95% of 2025 revenue, buoyed by insurance coverage for biologics and entrenched OTC culture, but CMS fee-schedule cuts and phenylephrine delisting temper near-term upside. Longer pollen seasons extend treatment windows, enlarging the allergic rhinitis drugs market beyond traditional spring peaks. Canada's approval of needle-free epinephrine and pediatric SLIT underscores regulatory openness to novel delivery, while Mexico's urbanization enlarges demand against a backdrop of rising private insurance.

Europe benefits from broadly reimbursed intranasal steroids and immunotherapy, yet national formularies vary, influencing uptake heterogeneity. Germany's full SLIT reimbursement contrasts with selective NHS coverage in the UK, shaping an uneven allergic rhinitis drugs market landscape. The EMA's low-sample guideline eases smaller-manufacturer entry, and OTC dual-action launches ahead of allergy seasons illustrate agile commercialization.

Asia-Pacific is the fastest-growing arena at 5.21% CAGR as house-dust-mite sensitization surpasses 85% in many coastal cities and weed-pollen positivity rises in northern China. Glenmark's China approval for Ryaltris and multinational alliances on SLIT herald deeper penetration of premium sprays and immunotherapies, yet affordability constraints keep generics pivotal. Regulatory agencies in China, Japan, and South Korea quicken reviews for pediatric formulations, further enlarging the allergic rhinitis drugs market. Middle East, Africa, and South America trail but show urban-center pockets of accelerated growth as disposable incomes climb.

1. ALK-Abello
2. Allergy Therapeutics
3. Bayer
4. Boehringer Ingelheim
5. Cipla
6. Dr. Reddy's Laboratories
7. Glenmark Pharmaceuticals
8. HAL Allergy Group
9. Haleon plc
10. Hikma Pharmaceuticals
11. HollisterStier Allergy
12. Kenvue
13. Organon
14. Perrigo Company
15. Sandoz Group
16. Sanofi
17. Stallergenes Greer
18. Teva Pharmaceutical Industries
19. Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support